Kasra Tajdaran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Kasra Tajdaran has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Tessa Gordon
Division of Plastic and Reconstructive Surgery, The Hospital for Sick Children, 555 University Ave, Toronto, Ontario M5G1X8, Canada; Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada; Program in Neuroscience, The Hospital for Sick Children Research Institute, Toronto, Ontario, Canada
6 shared publicationsGregory H. Borschel
Division of Plastic and Reconstructive Surgery, The Hospital for Sick Children, 555 University Ave, Toronto, Ontario M5G1X8, Canada; Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada; Division of Plastic and Reconstructive Surgery, Department of Surgery, University of Toronto, Toronto, Ontario, Canada; Program in Neuroscience, The Hospital for Sick Children Research Institute, Toronto, Ontario, Canada
5 shared publicationsMolly S. Shoichet
Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada; Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, Ontario, Canada
4 shared publications- Matthew D. Wood
Division of Plastic and Reconstructive Surgery, Department of Surgery, Washington University School of Medicine, St. Louis, MO 63110, USA
3 shared publications - Gregory Howard Borschel
Division of Plastic Surgery, Indiana University School of Medicine, Indianapolis, IN, USA
2 shared publications Katelyn Chan
Division of Plastic and Reconstructive Surgery, The Hospital for Sick Children, 555 University Ave, Toronto, Ontario M5G1X8, Canada; Institute of Biomaterials and Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada
2 shared publications
Latest Publications
- 1 July 2021
- Published by Elsevier in Experimental Neurology
- Vol. 341, 113680
Local FK506 drug delivery enhances nerve regeneration through fresh, unprocessed peripheral nerve allografts
- 1 July 2021
- Published by Elsevier in Experimental Neurology
- Vol. 341, 113680
Local FK506 drug delivery enhances nerve regeneration through fresh, unprocessed peripheral nerve allografts
- 1 September 2019
- Published by Elsevier in Experimental Neurology
- Vol. 319, 112817
Matrices, scaffolds, and carriers for protein and molecule delivery in peripheral nerve regeneration
- 1 September 2019
- Published by Elsevier in Experimental Neurology
- Vol. 319, 112817
Matrices, scaffolds, and carriers for protein and molecule delivery in peripheral nerve regeneration
- 7 December 2018
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 116 (2) , 405-414
Local FK506 dose‐dependent study using a novel three‐dimensional organotypic assay
Local administration of FK506, an FDA approved immunosuppressant with neuroregenerative properties, is a promising technique to achieve improved peripheral nerve regeneration while preventing the side effects associated with the systemic administration of this drug. Whilst considerable research has been devoted to the development of clinically suitable systems for local delivery of FK506 to the site of nerve injury and repair, the optimal dose of FK506 for enhancement of axon regeneration in the peripheral nerve has not yet been established. To this end, we devised a three‐dimensional (3D) organotypic assay capable of mimicking the peripheral nerve. This assay consisted of a neonatal rat dorsal root ganglion (DRG) extending its neurites into the native peripheral nerve scaffold provided by an acellular nerve allograft (ANA). A novel 3D compartmented cell culture system was adapted from the 3D organotypic assay to achieve local delivery of FK506 just to the growing neurites in vitro and establish the required local dose of FK506 for peripheral nerve regeneration. A bimodal dose response was observed by culturing the entire DRG‐ANA construct with media containing different concentrations of FK506. Low drug concentration of 1 pg/mL and high drug concentration of 100 ng/mL lead to the longest neurite extension in vitro. Furthermore, regardless of the FK506 concentration, concentrating the drug to the growing neurites resulted in significant increase in both neurite extension and neurite density, an effect that was not observed with the FK506 delivery to both neurites and neural cell bodies within DRG. The findings in this study provide valuable insight into the optimal local dose of FK506 for peripheral nerve regeneration. Furthermore, for the first time, this study suggests the potential interaction of FK506 with axons at the level of the growth cone.
- 7 December 2018
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 116 (2) , 405-414
Local FK506 dose‐dependent study using a novel three‐dimensional organotypic assay
Local administration of FK506, an FDA approved immunosuppressant with neuroregenerative properties, is a promising technique to achieve improved peripheral nerve regeneration while preventing the side effects associated with the systemic administration of this drug. Whilst considerable research has been devoted to the development of clinically suitable systems for local delivery of FK506 to the site of nerve injury and repair, the optimal dose of FK506 for enhancement of axon regeneration in the peripheral nerve has not yet been established. To this end, we devised a three‐dimensional (3D) organotypic assay capable of mimicking the peripheral nerve. This assay consisted of a neonatal rat dorsal root ganglion (DRG) extending its neurites into the native peripheral nerve scaffold provided by an acellular nerve allograft (ANA). A novel 3D compartmented cell culture system was adapted from the 3D organotypic assay to achieve local delivery of FK506 just to the growing neurites in vitro and establish the required local dose of FK506 for peripheral nerve regeneration. A bimodal dose response was observed by culturing the entire DRG‐ANA construct with media containing different concentrations of FK506. Low drug concentration of 1 pg/mL and high drug concentration of 100 ng/mL lead to the longest neurite extension in vitro. Furthermore, regardless of the FK506 concentration, concentrating the drug to the growing neurites resulted in significant increase in both neurite extension and neurite density, an effect that was not observed with the FK506 delivery to both neurites and neural cell bodies within DRG. The findings in this study provide valuable insight into the optimal local dose of FK506 for peripheral nerve regeneration. Furthermore, for the first time, this study suggests the potential interaction of FK506 with axons at the level of the growth cone.
- 1 January 2016
- Published by Elsevier in Acta Biomaterialia
- Vol. 29, 62-70
A glial cell line-derived neurotrophic factor delivery system enhances nerve regeneration across acellular nerve allografts
- 1 January 2016
- Published by Elsevier in Acta Biomaterialia
- Vol. 29, 62-70
A glial cell line-derived neurotrophic factor delivery system enhances nerve regeneration across acellular nerve allografts
- 24 September 2015
- Published by Wiley in Journal of Biomedical Materials Research Part A
- Vol. 104 (2) , 367-376
An engineered biocompatible drug delivery system enhances nerve regeneration after delayed repair
Localized drug delivery strategies could greatly benefit patients with peripheral nerve injury and could be easy for surgeons to implement. We developed a local drug delivery system (DDS) using drug‐loaded poly(lactic‐co‐glycolic acid) (PLGA) microspheres (MS) embedded in a fibrin gel. In an in vitro study, we investigated the biocompatibility of this DDS by performing a toxicity assay in which we incubated PC‐12 cells with the medium released from the DDS in vitro. In an in vivo study, this DDS was applied at the rat common peroneal (CP) nerve injury site to deliver exogenous glial cell line‐derived neurotrophic factor (GDNF) to the regenerating axons after delayed nerve repair. In vitro, PC‐12 cells incubated with released media samples from the DDS had similar viability to control cells cultured with normal media, demonstrating that the DDS was not toxic. In vivo, the numbers of motor and sensory neurons that regenerated their axons with empty MS treatment were the same as when there was no MS treatment. The DDS increased the numbers of regenerating motor‐ and sensory neurons to levels indistinguishable from those observed with immediate nerve repair. The DDS increased neuron regeneration to levels double those observed with negative control groups. This biocompatible, nontoxic, fibrin gel‐based DDS enhances outcomes following severe peripheral nerve injuries. © 2015 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 104A: 367–376, 2016.
- 24 September 2015
- Published by Wiley in Journal of Biomedical Materials Research Part A
- Vol. 104 (2) , 367-376
An engineered biocompatible drug delivery system enhances nerve regeneration after delayed repair
Localized drug delivery strategies could greatly benefit patients with peripheral nerve injury and could be easy for surgeons to implement. We developed a local drug delivery system (DDS) using drug‐loaded poly(lactic‐co‐glycolic acid) (PLGA) microspheres (MS) embedded in a fibrin gel. In an in vitro study, we investigated the biocompatibility of this DDS by performing a toxicity assay in which we incubated PC‐12 cells with the medium released from the DDS in vitro. In an in vivo study, this DDS was applied at the rat common peroneal (CP) nerve injury site to deliver exogenous glial cell line‐derived neurotrophic factor (GDNF) to the regenerating axons after delayed nerve repair. In vitro, PC‐12 cells incubated with released media samples from the DDS had similar viability to control cells cultured with normal media, demonstrating that the DDS was not toxic. In vivo, the numbers of motor and sensory neurons that regenerated their axons with empty MS treatment were the same as when there was no MS treatment. The DDS increased the numbers of regenerating motor‐ and sensory neurons to levels indistinguishable from those observed with immediate nerve repair. The DDS increased neuron regeneration to levels double those observed with negative control groups. This biocompatible, nontoxic, fibrin gel‐based DDS enhances outcomes following severe peripheral nerve injuries. © 2015 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 104A: 367–376, 2016.
- 1 May 2015
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 135, 91
Abstract 127
- 1 May 2015
- Published by Wolters Kluwer Health in Plastic and Reconstructive Surgery
- Vol. 135, 91
Abstract 127
- 7 April 2015
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 112 (9) , 1948-1953
A novel polymeric drug delivery system for localized and sustained release of tacrolimus (FK506)
Despite substantial improvement in microsurgical techniques for nerve repair, recovery after peripheral nerve injury is usually incomplete. FK506, an FDA approved immunosuppressant, improves functional recovery and reinnervation following peripheral nerve injury in animal models. However, systemically delivered FK506 causes undesirable global immunosuppression. We have, therefore, engineered a biodegradable local delivery system for FK506 using fibrin gel as a drug reservoir that could be placed at a site of nerve injury. FK506 was incorporated into fibrin gel in solubilized, particulated, and poly(lactic‐co‐glycolic) acid (PLGA) microspheres‐encapsulated forms. A tunable release of FK506 in the fibrin gel from days to weeks was observed with the rate of release being most rapid for the solubilized form and then the particulate form. The most prolonged period of release was seen with the PLGA microsphere‐encapsulated form. As analyzed by in vitro dorsal root ganglion (DRG) neurite extension assay, PLGA microsphere encapsulation of FK506 did not alter the drug's properties and the released FK506 maintained its bioactivity over the entire period of release. This study suggests that local delivery of FK506 with fibrin hydrogel could be used to enhance peripheral nerve regeneration. Biotechnol. Bioeng. 2015;112: 1948–1953.
- 7 April 2015
- Published by Wiley in Biotechnology and Bioengineering
- Vol. 112 (9) , 1948-1953
A novel polymeric drug delivery system for localized and sustained release of tacrolimus (FK506)
Despite substantial improvement in microsurgical techniques for nerve repair, recovery after peripheral nerve injury is usually incomplete. FK506, an FDA approved immunosuppressant, improves functional recovery and reinnervation following peripheral nerve injury in animal models. However, systemically delivered FK506 causes undesirable global immunosuppression. We have, therefore, engineered a biodegradable local delivery system for FK506 using fibrin gel as a drug reservoir that could be placed at a site of nerve injury. FK506 was incorporated into fibrin gel in solubilized, particulated, and poly(lactic‐co‐glycolic) acid (PLGA) microspheres‐encapsulated forms. A tunable release of FK506 in the fibrin gel from days to weeks was observed with the rate of release being most rapid for the solubilized form and then the particulate form. The most prolonged period of release was seen with the PLGA microsphere‐encapsulated form. As analyzed by in vitro dorsal root ganglion (DRG) neurite extension assay, PLGA microsphere encapsulation of FK506 did not alter the drug's properties and the released FK506 maintained its bioactivity over the entire period of release. This study suggests that local delivery of FK506 with fibrin hydrogel could be used to enhance peripheral nerve regeneration. Biotechnol. Bioeng. 2015;112: 1948–1953.